Mesa Laboratories, Inc. (MLAB) Stock Competitors & Peer Comparison
See (MLAB) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MLAB | $95.61 | +0.23% | 528.2M | 9.65 | $9.91 | +0.67% |
| SIRO | $109.97 | +0.00% | 22B | 32.42 | $3.39 | N/A |
| HIMS | $34.38 | -3.02% | 7.7B | -344.00 | -$0.10 | N/A |
| MMED | $15.29 | +1.59% | 4.3B | -9.86 | -$1.55 | N/A |
| NVST | $25.91 | +0.58% | 4.2B | 19.64 | $1.32 | N/A |
| CON | $31.55 | +0.48% | 4B | 21.91 | $1.44 | +0.79% |
| OMCL | $44.92 | -1.47% | 2B | 23.52 | $1.91 | N/A |
| DRTS | $12.71 | -2.08% | 1.1B | -18.97 | -$0.67 | N/A |
| BBNX | $17.03 | +3.65% | 758.9M | -11.28 | -$1.51 | N/A |
| LAB | $0.92 | -2.07% | 359.5M | -22.96 | -$0.04 | N/A |
Stock Comparison
MLAB vs SIRO Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, MLAB is priced at $95.61, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas SIRO's P/E ratio is 32.42. In terms of profitability, MLAB's ROE is +0.04%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, MLAB is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check SIRO's competition here
MLAB vs HIMS Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, HIMS has a market cap of 7.7B. Regarding current trading prices, MLAB is priced at $95.61, while HIMS trades at $34.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas HIMS's P/E ratio is -344.00. In terms of profitability, MLAB's ROE is +0.04%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, MLAB is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check HIMS's competition here
MLAB vs MMED Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, MMED has a market cap of 4.3B. Regarding current trading prices, MLAB is priced at $95.61, while MMED trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas MMED's P/E ratio is -9.86. In terms of profitability, MLAB's ROE is +0.04%, compared to MMED's ROE of -0.14%. Regarding short-term risk, MLAB is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check MMED's competition here
MLAB vs NVST Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, NVST has a market cap of 4.2B. Regarding current trading prices, MLAB is priced at $95.61, while NVST trades at $25.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas NVST's P/E ratio is 19.64. In terms of profitability, MLAB's ROE is +0.04%, compared to NVST's ROE of +0.02%. Regarding short-term risk, MLAB is less volatile compared to NVST. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check NVST's competition here
MLAB vs CON Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, CON has a market cap of 4B. Regarding current trading prices, MLAB is priced at $95.61, while CON trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas CON's P/E ratio is 21.91. In terms of profitability, MLAB's ROE is +0.04%, compared to CON's ROE of +0.46%. Regarding short-term risk, MLAB is more volatile compared to CON. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check CON's competition here
MLAB vs OMCL Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, OMCL has a market cap of 2B. Regarding current trading prices, MLAB is priced at $95.61, while OMCL trades at $44.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas OMCL's P/E ratio is 23.52. In terms of profitability, MLAB's ROE is +0.04%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, MLAB is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check OMCL's competition here
MLAB vs DRTS Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, DRTS has a market cap of 1.1B. Regarding current trading prices, MLAB is priced at $95.61, while DRTS trades at $12.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas DRTS's P/E ratio is -18.97. In terms of profitability, MLAB's ROE is +0.04%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, MLAB is less volatile compared to DRTS. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check DRTS's competition here
MLAB vs BBNX Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, BBNX has a market cap of 758.9M. Regarding current trading prices, MLAB is priced at $95.61, while BBNX trades at $17.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas BBNX's P/E ratio is -11.28. In terms of profitability, MLAB's ROE is +0.04%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, MLAB is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check BBNX's competition here
MLAB vs LAB Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, LAB has a market cap of 359.5M. Regarding current trading prices, MLAB is priced at $95.61, while LAB trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas LAB's P/E ratio is -22.96. In terms of profitability, MLAB's ROE is +0.04%, compared to LAB's ROE of -0.21%. Regarding short-term risk, MLAB is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check LAB's competition here
MLAB vs STXS Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, STXS has a market cap of 165.7M. Regarding current trading prices, MLAB is priced at $95.61, while STXS trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas STXS's P/E ratio is -9.97. In terms of profitability, MLAB's ROE is +0.04%, compared to STXS's ROE of -1.53%. Regarding short-term risk, MLAB is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check STXS's competition here
MLAB vs FONR Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, MLAB is priced at $95.61, while FONR trades at $19.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas FONR's P/E ratio is 19.09. In terms of profitability, MLAB's ROE is +0.04%, compared to FONR's ROE of +0.04%. Regarding short-term risk, MLAB is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check FONR's competition here
MLAB vs SNWV Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, SNWV has a market cap of 100.4M. Regarding current trading prices, MLAB is priced at $95.61, while SNWV trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas SNWV's P/E ratio is 35.39. In terms of profitability, MLAB's ROE is +0.04%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, MLAB is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check SNWV's competition here
MLAB vs LNSR Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, LNSR has a market cap of 71.8M. Regarding current trading prices, MLAB is priced at $95.61, while LNSR trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas LNSR's P/E ratio is 6.05. In terms of profitability, MLAB's ROE is +0.04%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, MLAB is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check LNSR's competition here
MLAB vs KDLY Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, MLAB is priced at $95.61, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas KDLY's P/E ratio is -15.48. In terms of profitability, MLAB's ROE is +0.04%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, MLAB is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check KDLY's competition here
MLAB vs NEUE Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, MLAB is priced at $95.61, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas NEUE's P/E ratio is -0.38. In terms of profitability, MLAB's ROE is +0.04%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, MLAB is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check NEUE's competition here
MLAB vs PARK Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, PARK has a market cap of 40.7M. Regarding current trading prices, MLAB is priced at $95.61, while PARK trades at $20.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas PARK's P/E ratio is 28.28. In terms of profitability, MLAB's ROE is +0.04%, compared to PARK's ROE of -0.24%. Regarding short-term risk, MLAB is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check PARK's competition here
MLAB vs EKSO Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, MLAB is priced at $95.61, while EKSO trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas EKSO's P/E ratio is -3.11. In terms of profitability, MLAB's ROE is +0.04%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, MLAB is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check EKSO's competition here
MLAB vs BEAT Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, BEAT has a market cap of 20.8M. Regarding current trading prices, MLAB is priced at $95.61, while BEAT trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas BEAT's P/E ratio is -1.08. In terms of profitability, MLAB's ROE is +0.04%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, MLAB is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check BEAT's competition here
MLAB vs STSSW Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, MLAB is priced at $95.61, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas STSSW's P/E ratio is -0.03. In terms of profitability, MLAB's ROE is +0.04%, compared to STSSW's ROE of N/A. Regarding short-term risk, MLAB is more volatile compared to STSSW. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check STSSW's competition here
MLAB vs PMC Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, PMC has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas PMC's P/E ratio is 47.90. In terms of profitability, MLAB's ROE is +0.04%, compared to PMC's ROE of +0.04%. Regarding short-term risk, MLAB is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check PMC's competition here
MLAB vs EVHC Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas EVHC's P/E ratio is -3.20. In terms of profitability, MLAB's ROE is +0.04%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, MLAB is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check EVHC's competition here
MLAB vs COTV Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, COTV has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas COTV's P/E ratio is 26.51. In terms of profitability, MLAB's ROE is +0.04%, compared to COTV's ROE of +0.14%. Regarding short-term risk, MLAB is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check COTV's competition here
MLAB vs AMSG Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas AMSG's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, MLAB is less volatile compared to AMSG. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check AMSG's competition here
MLAB vs SPNC Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas SPNC's P/E ratio is -23.91. In terms of profitability, MLAB's ROE is +0.04%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, MLAB is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check SPNC's competition here
MLAB vs CYNO Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas CYNO's P/E ratio is 108.96. In terms of profitability, MLAB's ROE is +0.04%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, MLAB is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check CYNO's competition here
MLAB vs SCAI Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas SCAI's P/E ratio is 64.66. In terms of profitability, MLAB's ROE is +0.04%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, MLAB is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check SCAI's competition here
MLAB vs STJ Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, STJ has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas STJ's P/E ratio is 36.51. In terms of profitability, MLAB's ROE is +0.04%, compared to STJ's ROE of +0.21%. Regarding short-term risk, MLAB is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check STJ's competition here
MLAB vs MEDC Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas MEDC's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to MEDC's ROE of N/A. Regarding short-term risk, MLAB is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check MEDC's competition here
MLAB vs ABAX Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas ABAX's P/E ratio is 70.62. In terms of profitability, MLAB's ROE is +0.04%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, MLAB is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check ABAX's competition here
MLAB vs EXAC Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, MLAB's ROE is +0.04%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, MLAB is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check EXAC's competition here
MLAB vs LDR Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, LDR has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas LDR's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to LDR's ROE of +1.17%. Regarding short-term risk, MLAB is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check LDR's competition here
MLAB vs DSCI Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas DSCI's P/E ratio is -0.01. In terms of profitability, MLAB's ROE is +0.04%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, MLAB is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check DSCI's competition here
MLAB vs MZOR Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas MZOR's P/E ratio is -70.18. In terms of profitability, MLAB's ROE is +0.04%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, MLAB is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check MZOR's competition here
MLAB vs SPAN Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas SPAN's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, MLAB is less volatile compared to SPAN. This indicates potentially lower risk in terms of short-term price fluctuations for MLAB.Check SPAN's competition here
MLAB vs ABCO Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas ABCO's P/E ratio is 0.52. In terms of profitability, MLAB's ROE is +0.04%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, MLAB is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check ABCO's competition here
MLAB vs LPNT Comparison July 2026
MLAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MLAB stands at 528.2M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, MLAB is priced at $95.61, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MLAB currently has a P/E ratio of 9.65, whereas LPNT's P/E ratio is 67.44. In terms of profitability, MLAB's ROE is +0.04%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, MLAB is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for MLAB.Check LPNT's competition here